In 2017, Immunovia announced impressing early results in the diagnostics of – and differentiation between – several different autoimmune diseases based on the IMMray™ technology platform. Consequently, the company decided to expand their strategy in the area of autoimmune disorders.
Currently, research for the purpose of developing tests for the early diagnostics of several autoimmune diseases based on the IMMray™ platform is carried out, within the company, or in associations with academia; with a focus on:
- Systemic Lupus Erythematosus (SLE)
- Reumatoid Arthritis (RA)
- Sjögrens Syndrome
Through collaboration with the University of Linköping, Immunovia has gained access to a large biobank with patient samples and clinical expertise within areas such as Rheumatoid Arthritis, Systemic Lupus Erythematosus (SLE), Vasculitis, Sjögrens Syndrome and autoimmune disorders in general.
Complementary studies and validation studies are currently ongoing in these areas.